Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Recruiting now · Phase 2/Phase 3

Conditions studied: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

In brief

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Key facts

Study ID

NCT06943755

Run by

Exelixis

People needed

440

Starts

2025-07-21

Expected to finish

2029-06-30

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Hospital — Phoenix, Arizona, United States (enrolling)
• The University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
• Cedars-Sinai Medical Center — Beverly Hills, California, United States (enrolling)
• Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
• Stanford Cancer Center — Palo Alto, California, United States (enrolling)
• UCLA Health - Santa Monica Cancer Care — Santa Monica, California, United States (enrolling)
• Kaiser Permanente Medical Center — Vallejo, California, United States (enrolling)
• Georgetown University — Washington D.C., District of Columbia, United States (enrolling)
• Mayo Clinic - Florida — Jacksonville, Florida, United States (enrolling)
• AdventHealth Orlando — Orlando, Florida, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• University of Kentucky Markey Cancer Center — Lexington, Kentucky, United States (enrolling)
• East Jefferson General Hospital — Metairie, Louisiana, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Henry Ford Cancer- Detroit — Detroit, Michigan, United States (enrolling)
• The Cancer and Hematology Centers — Grand Rapids, Michigan, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• Siteman Cancer Center — St Louis, Missouri, United States (enrolling)
• University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
• University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico, United States (enrolling)
• Roswell Park Cancer Institute — Buffalo, New York, United States (enrolling)
• Icahan School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
• University of Rochester Medical Center — Rochester, New York, United States (enrolling)
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
• The University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.